Omnicell, Inc. (NASDAQ:OMCL) PT Raised to $52.00 at Craig Hallum
Omnicell, Inc. (NASDAQ:OMCL) had its price target lifted by stock analysts at Craig Hallum from $46.00 to $52.00 in a note issued to investors on Friday, July 28th, The Fly reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective points to a potential upside of 1.86% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reissued a “buy” rating and issued a $47.00 price target on shares of Omnicell in a report on Tuesday, July 25th. TheStreet cut Omnicell from a “b-” rating to a “c+” rating in a research note on Thursday, May 4th. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Piper Jaffray Companies cut Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price target for the company. in a research report on Friday, April 21st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $49.00.
Omnicell (OMCL) opened at 51.05 on Friday. The company’s market cap is $1.90 billion. Omnicell has a 52-week low of $30.35 and a 52-week high of $51.20. The company’s 50-day moving average is $43.70 and its 200 day moving average is $40.34.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share for the quarter, hitting the consensus estimate of $0.02. The business had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the company earned $0.38 earnings per share. Equities analysts forecast that Omnicell will post $1.31 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Omnicell, Inc. (NASDAQ:OMCL) PT Raised to $52.00 at Craig Hallum” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/07/craig-hallum-boosts-omnicell-inc-nasdaqomcl-price-target-to-52-00-updated.html.
In related news, VP J Christopher Drew sold 10,625 shares of the business’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $40.97, for a total value of $435,306.25. Following the sale, the vice president now owns 152,057 shares in the company, valued at approximately $6,229,775.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Dan S. Johnston sold 16,400 shares of the company’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $40.67, for a total value of $666,988.00. Following the sale, the executive vice president now owns 61,696 shares in the company, valued at approximately $2,509,176.32. The disclosure for this sale can be found here. Insiders have sold 160,300 shares of company stock worth $7,190,201 in the last three months. 3.77% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of Omnicell during the first quarter worth about $125,000. LS Investment Advisors LLC boosted its stake in shares of Omnicell by 136.3% in the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock worth $145,000 after buying an additional 2,060 shares during the period. State of Alaska Department of Revenue boosted its stake in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock worth $165,000 after buying an additional 120 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in shares of Omnicell during the first quarter worth about $170,000. Finally, Turner Investments LLC bought a new stake in Omnicell during the second quarter valued at approximately $181,000. 96.35% of the stock is owned by hedge funds and other institutional investors.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.